Anemia and Diabetes in the Absence of Nephropathy
|
|
- Alaina Skinner
- 5 years ago
- Views:
Transcription
1 Pathophysiology/Complications O R I G I N A L A R T I C L E Anemia and Diabetes in the Absence of Nephropathy KATHRINE J. CRAIG, BSC(HONS), RN 1 JOHN D. WILLIAMS, MD, FRCP 1 STEPHEN G. RILEY, MD, MRCP 1 HILARY SMITH, RN 2 DAVID R. OWENS, MD 2 DEBBIE WORTHING, RN 1 IVOR CAVILL, MD 3 ALED O. PHILLIPS, MD, FRCP 1 OBJECTIVE Patients with diabetes commonly have a greater degree of anemia for their level of renal impairment than those presenting with other causes of renal failure. To clarify the contribution and differing roles of diabetes and nephropathy in the development of anemia in diabetic patients, we examined the hematologic and hematinic parameters of diabetic patients without nephropathy. RESEARCH DESIGN AND METHODS The study group was comprised of 62 patients with type 2 diabetes who had been followed for a median of 7 years. For the study, these patients had additional samples taken during their annual routine blood testing for the measurement of extra parameters, including serum ferritin, serum erythropoietin (Epo) levels, and the percentage of reticulocytes. These measurements were combined with the routine parameters Hb, hematocrit, HbA 1c, and glomerular filtration rate. RESULTS In all, 8 of the 45 male patients (17.8%) and 2 of the 17 female patients (11.8%) were classified as anemic (Hb 13g/dl and 11.5g/dl, respectively). Although only a small number of the patients had anemia as defined by normal values, a retrospective analysis of individual patients over time revealed a sustained though small decrease in Hb from initial presentation. A statistically significant difference in Epo levels (P by Kruskal-Wallis test) was observed from the group with the lowest (Hb 11.5) to that with the highest (Hb 14.5) Hb values, with a median Epo value of 37 (interquartile range 24 42) vs. 13 (9 15) IU/l, respectively. In contrast, there was no evidence of an increased reticulocyte response to higher levels of Epo (r [Pearsons], P 0.36). Reticulocyte counts ranged from 44 (38 57) to 76.5 (56 83) in the lowest and highest Hb groups, respectively. CONCLUSIONS Although only a small number of subjects in the group were overtly anemic, all subjects had an ongoing, small but significant decrease in Hb since presentation. This study of diabetic patients without nephropathy shows an expected increase in Epo production in response to lowering levels of Hb but without the expected reticulocyte response. In the U.K., as in the rest of the Western world, diabetes is the most prevalent cause of renal failure. Over the next 10 years, the number of patients with diabetes and end-stage renal disease is expected Diabetes Care 28: , 2005 From the 1 Institute of Nephrology, School of Medicine, Cardiff University, Cardiff, U.K.; the 2 Diabetes Research Unit, Llandough Hospital, Cardiff, U.K.; and the 3 Department of Haematology, University Hospital of Wales, Cardiff, U.K. Address correspondence and reprint requests to Dr. A.O. Phillips, Institute of Nephrology, University of Wales College of Medicine, Heath Park, Cardiff CF14 4XN, U.K. phillipsao@cf.ac.uk. Received for publication 24 November 2004 and accepted in revised form 4 February Abbreviations: Epo, erythropoietin; GFR, glomerular filtration rate. A table elsewhere in this issue shows conventional and Système International (SI) units and conversion factors for many substances by the American Diabetes Association. The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact. to double, causing a significant increase in the burden of care for this patient population (1). Although the prognosis with diabetic nephropathy has improved since early reports (2,3), there remains an excess mortality of times that of an otherwise matched population (4). Survival rates on dialysis remain poor, with up to 33% of patients dying within a year of starting dialysis (4). Furthermore, for patients who require renal replacement therapy, morbidity as assessed by hospitalization is 2 3 times greater than for nondiabetic patients with end-stage renal failure (2). This excess of morbidity and mortality in part relates to the high incidence of cardiovascular disease in this patient group (5). The identification of mechanisms underlying modifiable factors that may prevent or slow progression or improve patient survival in diabetic nephropathy has therefore become increasingly important. Patients presenting with diabetic nephropathy commonly have a greater degree of anemia for their degree of renal impairment than those presenting with other causes of renal failure, and anemia develops earlier in these patients than in those with renal impairment from other causes (6,7). Recent studies have identified anemia as a risk factor for the need for renal replacement therapy in diabetes (8); in addition, a lower Hb is significantly associated with a more rapid decline in the glomerular filtration rate (GFR) (9). Furthermore, treating anemia early in renal failure has been demonstrated to slow the rate of decline of renal function (10). Anemia also has a negative impact on patient survival, and is considered to be an important cardiovascular risk factor associated with renal disease. Understanding the pathogenesis of anemia associated with diabetes and nephropathy may therefore lead to opportunities for developing interventions to optimize outcomes in these patients. Many factors have been suggested as the reason for the earlier onset of anemia in patients with diabetes, including severe symptomatic autonomic neuropathy, causing efferent sympathetic denervation of the kidney and loss of appropriate erythropoietin (Epo) production; damage to the renal interstitium; systemic inflammation; and inhibition of Epo release. It has also been shown that a normochromic, normocytic anemia can occur before 1118 DIABETES CARE, VOLUME 28, NUMBER 5, MAY 2005
2 Craig and Associates Figure 1 Alteration in Hb levels over time in diabetic patients in the absence of nephropathy. Data are presented separately for male and female subjects. Hb at presentation represents the Hb value obtained at initial presentation of the patients to the diabetic services. Data represent medians and interquartile ranges, with open circles representing outliers ( 2 SDs from the population mean). evidence of renal impairment is present. To clarify the contribution of diabetes and nephropathy to anemia in patients with type 2 diabetes, we examined the hematologic and hematinic parameters of diabetic patients without nephropathy. A retrospective analysis was also performed in which we investigated the longitudinal changes in hematologic parameters of this patient group. RESEARCH DESIGN AND METHODS Participants were recruited from the Research Clinic of the Academic Diabetes Research Unit, Llandough Hospital, Cardiff, where patients are under long-term follow-up care. All patients had been followed for a minimum of 5 years. Written informed consent was obtained from 62 patients. All recruited patients had type 2 diabetes and had undergone exhaustive yearly health checks, including formal isotope measurement of GFR and assessment of proteinuria. GFR was measured after a single intravenous injection of 51 Cr-EDTA at t 0, with blood samples being drawn at 44, 120, 180, and 240 min. GFR was calculated by biexponential analysis of the 240-min fractional curve for 51 Cr-EDTA corrected to a standard body surface area of 1.73 m 2. At the subjects annual diabetes review, serum ferritin, serum Epo levels, and reticulocytes were measured as well as routine parameters including Hb, hematocrit, HbA 1c, and GFR. In addition, retrospective hematologic results were collected from the patient records for the period before recruitment. Statistical analysis was performed using SPSS for Windows, Vers All parameters were tested for distribution, and nonparametric analysis was undertaken where appropriate. Kruskal-Wallis tests were undertaken for k independent variables and Mann-Whitney tests were used for two independent variables. All values are given as medians (interquartile ranges). Correlation coefficients were measured using Pearson s correlation coefficient. The criterion for statistical significance was P RESULTS The median patient age was 62 (55 69) years with a 45:17 ratio of male-to-female patients. All patients had good glycemic control and diabetes duration of 7 (5 11) years. No patient tested positive for microalbuminuria or proteinuria at any time during the follow-up period. The GFR for all patients reflected normal renal function throughout the study. However, there was a statistically significant drop in GFR from presentation (from to ml/min; means SE; P 0.001) that reflected a decrease from a hyperfiltration state in most patients. Therefore, the absence of microalbuminuria and normal GFR excluded the development of incipient diabetic nephropathy over the course of the follow-up period. The study subjects were divided into anemic and nonanemic groups using normal ranges for male ( 13g/l) and female ( 11.5g/l) patients. At the time of the study, 8 of 45 male and 2 of 17 female (11.8%) patients were classified as anemic (17.8%). In contrast, at presentation, only 4 of the 62 patients were anemic (7%). Of the anemic patients, only one had an underlying chronic disorder (rheumatic disease) that explained the anemia. Although only a small number of the patients had anemia as defined by normal values at time of study, the retrospective analysis of individual patients DIABETES CARE, VOLUME 28, NUMBER 5, MAY
3 EPO resistance in diabetes were not the result of iron deficiency, the ferritin concentration was determined at the time of the study for all patients (Fig. 6). There was no difference in the ferritin concentration between the group with the lowest and that with the highest Hb levels, with none of the patient groups demonstrating iron deficiency as assessed by this parameter. Figure 2 Change in Hb levels from the presentation value for each individual patient. since presentation revealed a sustained though small decrease in Hb from initial presentation (Fig. 1); analysis of individual changes in Hb over time indicated that 36 of the 62 individuals (58.1%) had sustained a drop in Hb (Fig. 2). Serum Epo levels in relation to Hb levels at the time of follow-up are illustrated in Fig. 3. A significant negative correlation (Pearson s correlation coefficient 0.612) between Epo levels and Hb was demonstrated (P 0.01). These data suggest an appropriate Epo response to the fall in Hb, as Epo levels were higher in the lowest Hb group. Statistical analyses confirmed a statistically significant difference (P by Kruskal-Wallis) between the group with the lowest (Hb 11.5) to group with the highest (Hb 15.5) Hb values. Despite the increase in Epo in those patients with a fall in Hb, there was no reticulocyte response to the higher levels of Epo (Pearson s correlation coefficient 0.134; NS). The reticulocyte count was no different between the patient groups with the lowest and highest Hb levels (Fig. 4), and there was no relation between reticulocyte count and Epo concentration (Fig. 5) To ensure that the observed changes CONCLUSIONS Anemia is a common complication of chronic kidney disease. It is often more severe and occurs at an earlier stage in patients with diabetic nephropathy than in patients with chronic kidney disease of other causes. Numerous studies have addressed the interaction between diabetes and renal failure in its pathogenesis. The anemia associated with nephropathy results from Epo deficiency, which seems to develop in patients with type 1 diabetes who have even relatively normal levels of serum creatinine. Early Epo-deficiency anemia occurs in both type 1 and type 2 diabetes, although the prevalence may be higher in type 1 diabetes (6); however, most diabetic patients with Epo-deficiency have Figure 3 Relation between Epo levels and Hb at the time of patient recruitment into the study. Data represent medians and interquartile ranges, with open circles representing outliers ( 2 SDs from the population mean) DIABETES CARE, VOLUME 28, NUMBER 5, MAY 2005
4 Craig and Associates Figure 4 Relation between reticulocyte count and Hb levels at the time of patient recruitment into the study. Data represent medians and interquartile ranges, with open circles representing outliers ( 2 SDs from the population mean). type 2 diabetes because type 2 is more common than type 1 diabetes. There is also a greater prevalence of Epodeficiency anemia in women than in men, but this is not related to iron stores. In addition, Epo-deficiency anemia is associated with the presence of autonomic neuropathy in diabetic patients. In most studies to date, the predominant risk factor for the development of anemia in a diabetic population has been found to be the presence of renal disease, manifested as impaired renal function or albuminuria (11). Although a small number of patients in the study group were overtly anemic, it is interesting to note that 60% had an ongoing, small but significant decrease in Hb since presentation. This may be partly accounted for by the effect of age, which is known to affect Hb levels, but the prevalence differs markedly from that of a similarly aged Caucasian population by 2 6% (12). The levels of anemia found in this group of type 2 diabetic patients are similar to the levels described in a cohort of type 1 diabetic patients in the recently published study by Thomas et al. (11), where 14% of patients were found to be anemic. It is of note, however, that the study cohort of Thomas et al. contained patients with nephropathy of varying degrees, whereas the group studied within the current study had normal GFRs and no microalbuminuria. This study attempted to add to our understanding of the mechanisms behind the early onset of anemia in diabetic patients by separating the impact of diabetes from that of nephropathy. The group of patients studied had undergone intensive follow-up in a multidisciplinary diabetic clinic. Furthermore, as a cohort that was self-selected to attend the research clinic, they were a well-motivated and educated group of patients. In contrast to studies performed in patients with nephropathy, this study of diabetic patients without nephropathy showed a different picture in terms of Epo response. We demonstrated the expected normal increase in Epo production in response to lowering levels of Hb in our cohort of diabetic patients in the absence of nephropathy. This is in contrast to the characteristics of anemia associated with diabetic nephropathy, in which impaired function of Epoproducing fibroblasts associated with interstitial fibrosis (13) and a defect of anemia-sensing mechanisms associated with autonomic neuropathy (14) may both contribute to EPO deficiency. An analysis of the relation between Epo levels and the reticulocyte response in patients Figure 5 Relation between reticulocyte count and Epo levels at the time of patient recruitment into the study. Data represent medians and interquartile ranges, with open circles representing outliers ( 2 SDs from the population mean). DIABETES CARE, VOLUME 28, NUMBER 5, MAY
5 EPO resistance in diabetes Acknowledgments This work was supported by an unrestricted research grant by Ortho Biotech U.K. & Ireland. A.O.P. is supported by a GlaxoSmithKline Senior Fellowship. Parts of this study were presented in abstract form at the 37th annual meeting of the American Society of Nephrology, St. Louis, Missouri, 27 October to 1 November Figure 6 Relation between ferritin concentration and Hb levels at the time of patient recruitment into the study, confirming that all patients were iron replete. Data represent medians and interquartile ranges, with open circles representing outliers ( 2 SDs from the population mean). with chronic mild anemia of nondiabetic origin conducted by Souweine et al. (15) demonstrated a positive correlation (P 0.958) in patients with no or mild anemia. In our patient cohort, however, the rise in Epo was not accompanied by the expected normal reticulocyte response, suggesting a state of relative Epo resistance. Our data also suggest that diabetic patients, in the absence of renal disease, are able to mount an appropriate Epo response, consistent with the demonstration of an appropriate response to hypoxia previously reported (16). One of the most potent causes of suboptimal response to Epo is chronic and overt inflammation (17) associated with an increased production of cytokines, such as tumor necrosis factor-, interleukin-1, or interferon- (18), which might suppress erythrocyte stem cell proliferation (19). It is therefore interesting to speculate that overt inflammation associated with the diabetic state may contribute to Epo unresponsiveness before the onset of nephropathy. Although ferritin levels are not always an accurate reflection of iron status, levels in this patient group were within the normal range and no patient showed evidence of overt iron depletion. This finding is consistent with previous studies that failed to demonstrate iron deficiency in a mixed cohort of type 1 and 2 diabetic patients (20). These studies demonstrated elevated iron indexes to be more common in diabetic patients, suggesting that excess iron may have a role in the diabetes development. Recent studies have highlighted an association between anemia and the development and progression of diabetic nephropathy. There is also a high cardiovascular risk in patients with diabetic nephropathy and a clear association between anemia and abnormal cardiac function. It is therefore an important observation that the development of anemia in diabetes may predate any abnormality in renal function. Furthermore, understanding the mechanism by which this occurs may provide the opportunity to develop therapeutic options that may improve patient outcomes. References 1. Xue JL, Ma JZ, Louis TA, Collins AJ: Forecast of the number of patients with endstage renal disease in the United States to the year J Am Soc Nephrol 12: , Marcelli D, Spotti D, Conte F, Limido A, Lonati F, Malberti F, Locatelli F: Prognosis of diabetic patients on dialysis: analysis of Lombardy registry data. Nephrol Dial Transplant 10: , Ghavamian M, Gutch CF, Kopp KF, Kolff WJ: The sad truth about hemodialysis in diabetic nephropathy. JAMA 222: , Chantrel F, Enache I, Bouiller M, Kolb I, Kunz K, Petitjean P, Moulin B, Hannedouche T: Abysmal prognosis of patients with type 2 diabetes entering dialysis. Nephrol Dial Transplant 14: , Keith DS, Nichols GA, Gullion CM, Brown JB, Smith DH: Longitudinal follow-up and outcomes among a population with chronic kidney disease in a large managed care organization. Arch Intern Med 164: , Bosman DR, Winkler AS, Marsden JT, Macdougall IC, Watkins PJ: Anemia with erythropoietin deficiency occurs early in diabetic nephropathy. Diabetes Care 24: , Thomas MC, MacIsaac RJ, Tsalamandris C, Power D, Jerums G: Unrecognized anemia in patients with diabetes: a crosssectional survey. Diabetes Care 26: , Cusick M, Chew EY, Hoogwerf B, Agron E, Wu L, Lindley A, Ferris FL 3rd: Risk factors for renal replacement therapy in the Early Treatment Diabetic Retinopathy Study (ETDRS). Early Treatment Diabetic Retinopathy Study Report No. 26. Kidney Int 66: , Rossing K, Christensen PK, Hovind P, Tarnow L, Rossing P, Parving HH: Progression of nephropathy in type 2 diabetic patients. Kidney Int 66: , Gouva C, Nikolopoulos P, Ioannidis JP, Siamopoulos KC: Treating anemia early in renal failure patients slows the decline of renal function: a randomized controlled trial. Kidney Int 66: , Thomas MC, MacIsaac RJ, Tsalamandris C, Molyneaux L, Goubina I, Fulcher G, Yue D, Jerums G: Anemia in patients with type 1 diabetes. J Clin Endocrinol Metab 89: , DIABETES CARE, VOLUME 28, NUMBER 5, MAY 2005
6 Craig and Associates 12. Bennett SA, Magnus P: Trends in cardiovascular risk factors in Australia: results from the National Heart Foundation s Risk Factor Prevalence Study, Med J Aust 161: , Fioretto P, Mauer M, Brocco E, Velussi M, Frigato F, Muollo B, Sambataro M, Abaterusso C, Baggio B, Crepaldi G, Nosadini R: Patterns of renal injury in NIDDM patients with microalbuminuria. Diabetologia 39: , Winkler AS, Marsden J, Chaudhuri KR, Hambley H, Watkins PJ: Erythropoietin depletion and anaemia in diabetes mellitus. Diabet Med 16: , Souweine B, Serre AF, Philippe P, Conio N, Aumaitre O, Marcheix JC: Serum erythropoietin and reticulocyte counts in inflammatory process. Ann Med Interne (Paris) 146:8 12, Bosman DR, Osborne CA, Marsden JT, Macdougall IC, Gardner WN, Watkins PJ: Erythropoietin response to hypoxia in patients with diabetic autonomic neuropathy and non-diabetic chronic renal failure. Diabet Med 19:65 69, Kaysen GA: The microinflammatory state in uremia: causes and potential consequences. J Am Soc Nephrol 12: , Goicoechea M, Martin J, de Sequera P, Quiroga JA, Ortiz A, Carreno V, Caramelo C: Role of cytokines in the response to erythropoietin in hemodialysis patients. Kidney Int 54: , Zanjani ED, McGlave PB, Davies SF, Banisadre M, Kaplan ME, Sarosi GA: In vitro suppression of erythropoiesis by bone marrow adherent cells from some patients with fungal infection. Br J Haematol 50: , Thomas MC, MacIsaac RJ, Tsalamandris C, Jerums G: Elevated iron indices in patients with diabetes. Diabet Med 21: , 2004 DIABETES CARE, VOLUME 28, NUMBER 5, MAY
Anemia and neuropathy in type- 2 diabetes mellitus: A case control study
Original Research Paper IJRRMS 203;3(3) Anemia and neuropathy in type- 2 diabetes mellitus: A case control study Sinha Babu A, Chakrabarti A, Karmakar RN ABSTRACT Background: Albuminuria and retinopathy,
More informationAnemia With Erythropoietin Deficiency Occurs Early in Diabetic Nephropathy
Pathophysiology/Complications O R I G I N A L A R T I C L E Anemia With Erythropoietin Deficiency Occurs Early in Diabetic Nephropathy DEBORAH R. BOSMAN, MBBS 1 ANDREA S. WINKLER, MBBS 1 JOANNE T. MARSDEN,
More informationCHRONIC ANEMIA IS A COMMON finding
ORIGINAL INVESTIGATIONS Pathogenesis and Treatment of Kidney Disease and Hypertension The Epidemiology of Hemoglobin Levels in Patients With Type 2 Diabetes Merlin C. Thomas, MBChB, PhD, FRACP, Con Tsalamandris,
More informationDiabetes and renal disease: who does what?
CLINICAL PRACTICE Clinical Medicine 2013, Vol 13, No 5: 460 4 Diabetes and renal disease: who does what? Ruth K Jones, David Hampton, Daniel J O Sullivan and Aled O Phillips ABSTRACT Care of patients with
More informationRisk Factors in the Progression of Chronic Kidney Disease
Risk Factors in the Progression of Chronic Kidney Disease a report by Rainer Düsing Professor, Faculty of Medicine, University of Bonn DOI:10.17925/EE.2006.00.02.1e Chronic kidney disease (CKD) is a complex,
More informationInvited Revie W. Diabetic nephropathy: the modulating influence of glucose on transforming factor D production
Histol Histopathol (1 998) 13: 565-574 Histology and Histopathology Invited Revie W Diabetic nephropathy: the modulating influence of glucose on transforming factor D production A.O. Phillips lnstitute
More informationPrevalence of anemia and cardiovascular diseases in chronic kidney disease patients: a single tertiary care centre study
International Journal of Advances in Medicine Sathyan S et al. Int J Adv Med. 2017 Feb;4(1):247-251 http://www.ijmedicine.com pissn 2349-3925 eissn 2349-3933 Original Research Article DOI: http://dx.doi.org/10.18203/2349-3933.ijam20170120
More informationClinical Study Factors Associated with the Decline of Kidney Function Differ among egfr Strata in Subjects with Type 2 Diabetes Mellitus
International Endocrinology Volume 2012, Article ID 687867, 6 pages doi:10.1155/2012/687867 Clinical Study Factors Associated with the Decline of Kidney Function Differ among egfr Strata in Subjects with
More informationAnaemia in diabetes: is there a rationale to TREAT?
Diabetologia (26) 49: 1151 1157 DOI 1.17/s125-6-215-6 FOR DEBATE M. C. Thomas. M. E. Cooper. K. Rossing. H. H. Parving Anaemia in diabetes: is there a rationale to TREAT? Received: 21 August 25 / Accepted:
More informationImpaired protein tolerance test as a marker of early renal dysfunction in type 2 diabetes mellitus
Original Research Article Impaired protein tolerance test as a marker of early renal dysfunction in type 2 diabetes mellitus Devabhaktuni Siva Sankar 1, Shaik Khaja Rassul 1* 1 Assistant Professor of Medicine,
More informationANEMIA & HEMODIALYSIS
ANEMIA & HEMODIALYSIS The anemia of CKD is, in most patients, normocytic and normochromic, and is due primarily to reduced production of erythropoietin by the kidney and to shortened red cell survival.
More informationThe Diabetes Kidney Disease Connection Missouri Foundation for Health February 26, 2009
The Diabetes Kidney Disease Connection Missouri Foundation for Health February 26, 2009 Teresa Northcutt, RN BSN Primaris Program Manager, Prevention - CKD MO-09-01-CKD This material was prepared by Primaris,
More informationPublished trials point to a detrimental relationship
ANEMIA, CHRONIC KIDNEY DISEASE, AND CARDIOVASCULAR DISEASE: THE CLINICAL TRIALS Steven Fishbane, MD* ABSTRACT Clinical trials have shown a strong detrimental relationship among anemia, chronic kidney disease
More informationScreening and early recognition of CKD. John Ngigi (FISN) Kidney specialist
Screening and early recognition of CKD John Ngigi (FISN) Kidney specialist screening Why? Who? When? How? Primary diagnosis for patients who start dialysis Other 10% Glomerulonephritis 13% No. of dialysis
More informationThe hypertensive kidney and its Management
The hypertensive kidney and its Management Dr H0 Chung Ping Hypertension Management Seminar 20061124 Hypertensive kidney Kidney damage asymptomatic till late stage Viscous cycle to augment renal damage
More informationStudy of anaemia in type 2 diabetes mellitus
International Journal of Research in Medical Sciences Kaushik D et al. Int J Res Med Sci. 2018 May;6(5):1529-1533 www.msjonline.org pissn 2320-6071 eissn 2320-6012 Original Research Article DOI: http://dx.doi.org/10.18203/2320-6012.ijrms20181428
More informationEfficacy and tolerability of oral Sucrosomial Iron in CKD patients with anemia. Ioannis Griveas, MD, PhD
Efficacy and tolerability of oral Sucrosomial Iron in CKD patients with anemia Ioannis Griveas, MD, PhD Anaemia is a state in which the quality and/or quantity of circulating red blood cells are below
More informationPublished trials point to a detrimental relationship
ANEMIA, CHRONIC KIDNEY DISEASE, AND CARDIOVASCULAR DISEASE: THE CLINICAL TRIALS Steven Fishbane, MD* ABSTRACT Clinical trials have shown a strong detrimental relationship among anemia, chronic kidney disease
More informationPublished Online 2013 July 24. Research Article
Nephro-Urology Monthly. 2013 September; 5(4):913-7. Published Online 2013 July 24. DOI: 10.5812/numonthly.12038 Research Article Comparative Study of Intravenous Iron Versus Intravenous Ascorbic Acid for
More informationThe CARI Guidelines Caring for Australasians with Renal Impairment. ACE Inhibitor and Angiotensin II Antagonist Combination Treatment GUIDELINES
ACE Inhibitor and Angiotensin II Antagonist Combination Treatment Date written: September 2004 Final submission: September 2005 Author: Kathy Nicholls GUIDELINES No recommendations possible based on Level
More informationThe Incidence of Anemia and the Impact of Poor Glycemic Control in Type-2 Diabetic Patients with Renal Insufficiency
The Incidence of and the Impact of Poor Glycemic Control in Type-2 Diabetic Patients with Renal Insufficiency Babatunde Ishola Adejumo a, Uchechukwu Dimkpa b *, Chinwe Obianuju Ewenighi c, Tosan Amos Erhabor
More informationADVANCES. Annual reports from the Centers for. In Anemia Management. Anemia Management in the United States: Is There Opportunity for Improvement?
ADVANCES Vol. 1 No.1 22 We are pleased to introduce our newest NPA publication, Advances in Anemia Management. This quarterly publication will address contemporary issues relating to the treatment of anemia
More informationAdam T. Whaley-Connell, MD, James R. Sowers, MD, Joseph A. Vassalotti, MD, Moro O. Salifu, MD, MPH, Suying Li, PhD,
Prevalence and Associations of of CKD: Kidney Early Evaluation Program (KEEP) and National Health and Nutrition Examination Survey (NHANES) 1999-2004 1 Samy I. McFarlane, MD, MPH, Shu-Cheng Chen, MS, 2
More informationIron Status in Chronic Renal Failure with Anemia
Chattagram Maa-O-Shishu Hospital Medical College Journal DOI: 10.11566/cmosh.2013.1201.12 Original Article Iron Status in Chronic Renal Failure with Anemia Shaheda Khanam 1 * Noorzahan Begum 2 AMM Ehteshamul
More informationMasatoshi Kawashima 1, Koji Wada 2, Hiroshi Ohta 2, Rika Moriya 3 and Yoshiharu Aizawa 1. Journal of Occupational Health
176 J Occup Health, Vol. 54, 2012 J Occup Health 2012; 54: 176 180 Journal of Occupational Health Evaluation of Validity of the Urine Dipstick Test for Identification of Reduced Glomerular Filtration Rate
More informationComment on European Renal Best Practice Position Statement on Anaemia Management in Chronic Kidney Disease.
Comment on European Renal Best Practice Position Statement on Anaemia Management in Chronic Kidney Disease. Goldsmith D, Blackman A, Gabbay F, June 2013 Kidney Disease: Improving Global Outcomes (KDIGO)
More information(renoprotective (end-stage renal disease, ESRD) therapies) (JAMA)
[1], 1., 2. 3. (renoprotective (end-stage renal disease, ESRD) therapies) (JAMA) (multiple risk (renal replacement therapy, RRT) factors intervention treatment MRFIT) [2] ( 1) % (ESRD) ( ) ( 1) 2001 (120
More informationFigure 1 LVH: Allowed Cost by Claim Volume (Data generated from a Populytics analysis).
Chronic Kidney Disease (CKD): The New Silent Killer Nelson Kopyt D.O. Chief of Nephrology, LVH Valley Kidney Specialists For the past several decades, the health care needs of Americans have shifted from
More informationManagement of anemia in CKD. Masaomi Nangaku Division of Nephrology and Endocrinology the University of Tokyo Graduate School of Medicine, Japan
Management of anemia in CKD Masaomi Nangaku Division of Nephrology and Endocrinology the University of Tokyo Graduate School of Medicine, Japan Shiga toxin Kiyoshi Shiga 1871-1957 Shiga toxin binds to
More informationAgroup of clinicians, researchers, ... REPORT... Chronic Kidney Disease: Stating the Managed Care Case for Early Treatment
... REPORT... Chronic Kidney Disease: Stating the Managed Care Case for Early Treatment Discussion and Consensus of Presentations of Economic Analyses, Managed Care Organization Case Studies, and Opportunities
More informationLong-term outcomes in nondiabetic chronic kidney disease
original article http://www.kidney-international.org & 28 International Society of Nephrology Long-term outcomes in nondiabetic chronic kidney disease V Menon 1, X Wang 2, MJ Sarnak 1, LH Hunsicker 3,
More informationKey words: Diabetes, Anaemia, Glycemic Control, HbA1c, Micro and Macro Vascular Complications.
Original Article Study of Anaemia in Type II Diabetes Mellitus in Relation to Glycemic Control Karan Bhargav 1*, Krishna Baruah 2, Pramod Kumar Agrawal 2, Faiyaz Alam 3, Shruti Sonal 1, Abhisek Kumar 1,
More informationTREAT THE KIDNEY TO SAVE THE HEART. Leanna Tyshler, MD Chronic Kidney Disease Medical Advisor Northwest Kidney Centers February 2 nd, 2009
TREAT THE KIDNEY TO SAVE THE HEART Leanna Tyshler, MD Chronic Kidney Disease Medical Advisor Northwest Kidney Centers February 2 nd, 2009 1 ESRD Prevalent Rates in 1996 per million population December
More informationKidney International, Vol. 66 (2004), pp Report Number 7 (Ophthalmology 98: , 1991)
Kidney International, Vol. 66 (2004), pp. 1173 1179 Risk factors for renal replacement therapy in the Early Treatment Diabetic Retinopathy Study (ETDRS), Early Treatment Diabetic Retinopathy Study Report
More informationSHORT COMMUNICATION. G. Joshy & P. Dunn & M. Fisher & R. Lawrenson
Diabetologia (2009) 52:1474 1478 DOI 10.1007/s00125-009-1380-1 SHORT COMMUNICATION Ethnic differences in the natural progression of nephropathy among diabetes patients in New Zealand: hospital admission
More informationEvaluation of Hematological Parameters and Iron Status among Renal Failure Patients Attending Ribat National Hospital Khartoum, Sudan
EUROPEAN ACADEMIC RESEARCH Vol. III, Issue 11/ February 216 ISSN 2286-4822 www.euacademic.org Impact Factor: 3.4546 (UIF) DRJI Value: 5.9 (B+) Evaluation of Hematological Parameters and Iron Status among
More informationRole of High-sensitivity C-reactive Protein as a Marker of Inflammation in Pre-dialysis Patients of Chronic Renal Failure
ORIGINAL ARTICLE JIACM 2009; 10(1 & 2): 18-22 Abstract Role of High-sensitivity C-reactive Protein as a Marker of Inflammation in Pre-dialysis Patients of Chronic Renal Failure N Nand*, HK Aggarwal**,
More informationPART ONE. Peritoneal Kinetics and Anatomy
PART ONE Peritoneal Kinetics and Anatomy Advances in Peritoneal Dialysis, Vol. 22, 2006 Paul A. Fein, Irfan Fazil, Muhammad A. Rafiq, Teresa Schloth, Betty Matza, Jyotiprakas Chattopadhyay, Morrell M.
More informationThe CARI Guidelines Caring for Australasians with Renal Impairment. Antihypertensive therapy in diabetic nephropathy GUIDELINES
Antihypertensive therapy in diabetic nephropathy Date written: September 2004 Final submission: September 2005 Author: Kathy Nicholls GUIDELINES a. Adequate control of blood pressure (BP) slows progression
More informationPatients with chronic kidney disease (CKD) are
CLINICAL INTERVENTIONS TO REDUCE CARDIOVASCULAR RISK IN PATIENTS WITH KIDNEY DISEASE Jeffrey S. Berns, MD* ABSTRACT Although the specific mechanisms by which chronic kidney disease (CKD) and cardiovascular
More informationIron Markers in Patients with Advance Chronic Kidney Disease on First Dialysis at Shaikh Zayed Hospital, Lahore
Proceeding S.Z.P.G.M.I. Vol: 29(2): pp. 83-87, 2015. Iron Markers in Patients with Advance Chronic Kidney Disease on First Dialysis at Waqar Ahmad, Muhammad Rizwan Ul Haque, Abad Ur Rehman and Sammiullah
More informationMANAGERIAL. Potential Application of the National Kidney Foundation s Chronic Kidney Disease Guidelines in a Managed Care Setting
Potential Application of the National Kidney Foundation s Chronic Kidney Disease Guidelines in a Managed Care Setting Micah L. Thorp, DO, MPH; and Loris Eastman, RN, CNN Chronic kidney disease (CKD) is
More informationEffects of smoking on renal function in patients with type 1 and type 2 diabetes mellitus
Nephrol Dial Transplant (2005) 20: 2414 2419 doi:10.1093/ndt/gfi022 Advance Access publication 26 July 2005 Original Article Effects of smoking on renal function in patients with type 1 and type 2 diabetes
More informationChronic kidney disease (CKD) has received
Participant Follow-up in the Kidney Early Evaluation Program (KEEP) After Initial Detection Allan J. Collins, MD, FACP, 1,2 Suying Li, PhD, 1 Shu-Cheng Chen, MS, 1 and Joseph A. Vassalotti, MD 3,4 Background:
More informationFactors Affecting Progression of Renal Failure in Patients With Type 2 Diabetes
Pathophysiology/Complications O R I G I N A L A R T I C L E Factors Affecting Progression of Renal Failure in Patients With Type 2 Diabetes HIDEKI UEDA, MD 1 EIJI ISHIMURA, MD 2 TETSUO SHOJI, MD 1 MASANORI
More informationStages of chronic kidney disease
For mass reproduction, content licensing and permissions contact Dowden Health Media. Jonathan J. Taliercio, DO Department of Nephrology and Hypertension, Cleveland Clinic, Cleveland, Ohio talierj@ccf.org
More informationDoes autonomic neuropathy play a role in erythropoietin regulation in non-proteinuric Type 2 diabetic patients?
DOI: 10.1111/j.1464-5491.2004.01306.x Does autonomic neuropathy play a role in Oxford, DME Diabetic 0742-3071 Blackwell 21 Original Erythropoietin UK Article article Medicine Publishing, and autonomic
More informationPrevalence of anemia and dyslipidemia in patients with Diabetes Mellitus Type 2
Original Research Article Prevalence of anemia and dyslipidemia in patients with Diabetes Mellitus Type 2 Gunvanti Rathod 1, Kamlesh Shah 2* 1 Associate Professor, 2 Professor and Head Department of Pathology,
More informationMaintenance intravenous iron therapy in pediatric hemodialysis patients Morgan H E, Gautam M, Geary D F
Maintenance intravenous iron therapy in pediatric hemodialysis patients Morgan H E, Gautam M, Geary D F Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion
More informationHaematological profile of diabetes and non-diabetes patients in rural tertiary centre
International Journal of Advances in Medicine Kumar HS et al. Int J Adv Med. 2017 Oct;4(5):1271-1275 http://www.ijmedicine.com pissn 2349-3925 eissn 2349-3933 Original Research Article DOI: http://dx.doi.org/10.18203/2349-3933.ijam20174111
More informationAdvances in Environmental Biology
Advances in Environmental Biology, 9() November 15, Pages: 191-195 AENSI Journals Advances in Environmental Biology ISSN-1995-75 EISSN-199-1 Journal home page: http://www.aensiweb.com/aeb/ Effects of Active
More informationManagement of anemia in CKD
Management of anemia in CKD Pierre Cochat, MD PhD Professor of Pediatrics Chair, Pediatrics & Pediatric Surgery Department Head, Center for Rare Renal Diseases Néphrogones Hospices Civils de Lyon & University
More informationSUPPLEMENTARY DATA. Supplementary Table S1. Clinical characteristics of the study subjects.*
Supplementary Table S1. Clinical characteristics of the study subjects.* T2D ND n (F/M) 66 (21/45) 25 (7/18) Age (years) 61.8 ± 6.9 49.4 ± 7.3 # Body weight (kg) 95 ± 16 105 ± 13 # Body mass index (kg.
More informationClinical Study Plasma 25-Hydroxyvitamin D Is Independently Associated with Hemoglobin Concentration in Male Subjects with Type 2 Diabetes Mellitus
International Endocrinology Volume 2011, Article ID 362981, 5 pages doi:10.1155/2011/362981 Clinical Study Plasma 25-Hydroxyvitamin D Is Independently Associated with Hemoglobin Concentration in Male Subjects
More informationEpogen / Procrit. Epogen / Procrit (epoetin alfa) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.10.06 Section: Prescription Drugs Effective Date: April1, 2014 Subject: Epogen / Procrit Page: 1 of 7
More informationPrevention And Treatment of Diabetic Nephropathy. MOH Clinical Practice Guidelines 3/2006 Dr Stephen Chew Tec Huan
Prevention And Treatment of Diabetic Nephropathy MOH Clinical Practice Guidelines 3/2006 Dr Stephen Chew Tec Huan Prevention Tight glucose control reduces the development of diabetic nephropathy Progression
More informationIN THE LAST few decades, several important
Anemia Management for Hemodialysis Patients: Kidney Disease Outcomes Quality Initiative (K/DOQI) Guidelines and Dialysis Outcomes and Practice Patterns Study (DOPPS) Findings Francesco Locatelli, MD, Ronald
More informationTRENDS IN RENAL REPLACEMENT THERAPY IN BOSNIA AND HERZEGOVINA
& TRENDS IN RENAL REPLACEMENT THERAPY IN BOSNIA AND HERZEGOVINA 2002-2008 Halima Resić* 1, Enisa Mešić 2 1 Clinic for Hemodialysis, University of Sarajevo Clinics Centre, Bolnička 25, 71000 Sarajevo, Bosnia
More informationUtilizing Sysmex RET He to Evaluate Anemia in Cancer Patients
Utilizing Sysmex RET He to Evaluate Anemia in Cancer Patients Ellinor I. Peerschke, Ph.D., F.A.H.A. Vice Chair, Laboratory Medicine Chief, Hematology & Coagulation Laboratory Services Memorial Sloan Kettering
More informationKengo Furuichi, Miho Shimizu, Akinori Hara, Tadashi Toyama and Takashi Wada
doi: 10.2169/internalmedicine.1132-18 http://internmed.jp REVIEW ARTICLE Diabetic Nephropathy: A Comparison of the Clinical and Pathological Features between the CKD Risk Classification and the Classification
More informationAnaemia & Cancer. John de Vos Consultant Haematologist RSCH
Anaemia & Cancer John de Vos Consultant Haematologist RSCH overview Definitions & setting the scene Causes Consequences Biology Treatment Personal approach Patient Clinical team Anaemia - Definition :
More informationThe Egyptian Journal of Hospital Medicine (January 2018) Vol. 70, Page 92-96
The Egyptian Journal of Hospital Medicine (January 2018) Vol. 70, Page 92-96 Effect of HCV Infection Versus HBV Infection on the Response to Erythropoietin Therapy in The Treatment of Anemia in Prevalent
More informationOriginal Article Anemia management trends in patients on peritoneal dialysis in the past 10 years
Int J Clin Exp Med 2015;8(10):18050-18057 www.ijcem.com /ISSN:1940-5901/IJCEM0011104 Original Article Anemia management trends in patients on peritoneal dialysis in the past 10 years Huaye Liu, Yao Yao,
More informationImpact of correction of anemia on major complication of chronic renal diseases
Original article: Impact of correction of anemia on major complication of chronic renal diseases Md Hamid Ali, Atanu Roy Chaudhry, Kapildev Mondal, Arijit Sinha Department of General Medicine, Murshidabad
More informationRenal histologic changes and the outcome in patients with diabetic nephropathy
NDT Advance Access published July 25, 2014 Nephrol Dial Transplant (2014) 0: 1 10 doi: 10.1093/ndt/gfu250 Original Article Renal histologic changes and the outcome in patients with diabetic nephropathy
More informationErythropoiesis-stimulating Agents and Anemia in Patients with Non-dialytic Chronic Kidney Disease
ORIGINAL ARTICLE Nephrology http://dx.doi.org/1.3346/jkms.216.31.1.55 J Korean Med Sci 216; 31: 55- Erythropoiesis-stimulating Agents and Anemia in Patients with Non-dialytic Chronic Kidney Disease Sun
More informationThe CARI Guidelines Caring for Australians with Renal Impairment. Specific effects of calcium channel blockers in diabetic nephropathy GUIDELINES
Specific effects of calcium channel blockers in diabetic nephropathy Date written: September 2004 Final submission: September 2005 Author: Kathy Nicholls GUIDELINES a. Non-dihydropyridine calcium channel
More informationTSAT PROJECT Shean Strong, QI Director Lisle Mukai, QI Coordinator
Southern California Renal Disease Council, Inc. ESRD Network 18 TSAT PROJECT Shean Strong, QI Director Lisle Mukai, QI Coordinator TSAT 6255 West Sunset blvd Los Angeles, California i 90028 11/24/2010
More informationCurrent situation and future of renal anemia treatment. FRANCESCO LOCATELLI
Antalya May 20, 2010 12 National Congress of Turkish Society of Hypertension and Renal Disease Current situation and future of renal anemia treatment. FRANCESCO LOCATELLI Department of Nephrology, Dialysis
More informationIntroduction to Clinical Diagnosis Nephrology
Introduction to Clinical Diagnosis Nephrology I. David Weiner, M.D. C. Craig and Audrae Tisher Chair in Nephrology Professor of Medicine and Physiology and Functional Genomics University of Florida College
More information27/01/2019. Anaemia, Transfusion and TACO Lise Estcourt. Anaemia. What is anaemia?
Anaemia, Transfusion and TACO Lise Estcourt 1 Anaemia 2 What is anaemia? 3 1 Anaemia according to WHO 4 Anaemia in palliative care Common (77% men 68% women) Symptoms often non-specific Some causes potentially
More informationThe Changing Clinical Landscape of Anemia Management in Patients With CKD: An Update From San Diego Presentation 1
Presentation 1 The following is a transcript from a web-based CME-certified multimedia activity. Interactivity applies only when viewing the activity online. This activity is supported by educational grants
More informationAnaemia in the ICU: Is there an alternative to using blood transfusion?
Anaemia in the ICU: Is there an alternative to using blood transfusion? Tim Walsh Professor of Critical Care, Edinburgh University World Health Organisation grading of the severity of anaemia Grade of
More informationDefining risk factors associated with renal and cognitive dysfunction Joosten, Johanna Maria Helena
University of Groningen Defining risk factors associated with renal and cognitive dysfunction Joosten, Johanna Maria Helena IMPORTANT NOTE: You are advised to consult the publisher's version (publisher's
More informationResearch Journal of Pharmaceutical, Biological and Chemical Sciences
Research Journal of Pharmaceutical, Biological and Chemical Sciences Study of Improvement in Quality of Life with Recombinant Erythropoietin in Chronic End Stage Renal Failure Patients. Ratna Palit 1 *,
More informationEvidence-based practice in nephrology : Meta-analysis
Evidence-based practice in nephrology : Meta-analysis Paweena Susantitaphong, MD,Ph.D 1-3 1 Associate Professor, Division of Nephrology, Department of Medicine, King Chulalongkorn Memorial Hospital, Chulalongkorn
More informationOnce-weekly darbepoetin alfa is as effective as three-times weekly epoetin
Artigo Original ONCE-WEEKLY DARBEPOETIN ALFA IS AS EFFECTIVE AS THREE-TIMES WEEKLY EPOETIN Rev Port Nefrol Hipert 2004; 18 (1): 33-40 Once-weekly darbepoetin alfa is as effective as three-times weekly
More informationINFLUENCE OF LOW PROTEIN DIET IN IMPROVING ANEMIA TREATED WITH ERYTHROPOETIN
INFLUENCE OF LOW PROTEIN DIET IN IMPROVING ANEMIA TREATED WITH ERYTHROPOETIN, Idrizi A, Barbullushi M, Gjyzari A, Duraku A Department of Nephrology, University Hospital Center, Tirana, Albania Introduction
More informationEvidence Table. Study Type: Randomized controlled trial. Study Aim: To compare frequent nocturnal hemodialysis and conventional in-center dialysis.
Evidence Table Clinical Area: Reference: Frequent home dialysis Culleton BF, Walsh M, Klarenbach SW et al. Effect of frequent nocturnal hemodialysis vs conventional hemodialysis on left ventricular mass
More informationWORLD JOURNAL OF PHARMACOLOGICAL RESEARCH AND TECHNOLOGY Anemia in CKD: A Review
Review Article ISSN: 2347-4882 WORLD JOURNAL OF PHARMACOLOGICAL RESEARCH AND TECHNOLOGY Anemia in CKD: A Review Supriya Mor* 1, Prashant Mor 2, Anupama Diwan 1 1 School of Pharmaceutical Sciences, Apeejay
More informationAnalysis on the mechanism of reduced nephron number and the pathological progression of chronic renal failure in Astrin deficient rats
Analysis on the mechanism of reduced nephron number and the pathological progression of chronic renal failure in Astrin deficient rats Summary of Doctoral Thesis Hidenori Yasuda Graduate School of Veterinary
More informationThe CARI Guidelines Caring for Australasians with Renal Impairment. Specific management of IgA nephropathy: role of fish oil
Specific management of IgA nephropathy: role of fish oil Date written: July 2005 Final submission: September 2005 Author: Merlin Thomas GUIDELINES Early and prolonged treatment with fish oil may retard
More informationThe CARI Guidelines Caring for Australasians with Renal Impairment. Protein Restriction to prevent the progression of diabetic nephropathy GUIDELINES
Protein Restriction to prevent the progression of diabetic nephropathy Date written: September 2004 Final submission: September 2005 Author: Kathy Nicholls GUIDELINES a. A small volume of evidence suggests
More informationObjectives. Pre-dialysis CKD: The Problem. Pre-dialysis CKD: The Problem. Objectives
The Role of the Primary Physician and the Nephrologist in the Management of Chronic Kidney Disease () By Brian Young, M.D. Assistant Clinical Professor of Medicine David Geffen School of Medicine at UCLA
More informationResearch Article Erythrocyte and Reticulocyte Indices on the LH 750 as Potential Markers of Functional Iron Deficiency
Anemia Volume 2010, Article ID 625919, 7 pages doi:10.1155/2010/625919 Research Article Erythrocyte and Reticulocyte Indices on the LH 750 as Potential Markers of Functional Iron Deficiency Eloísa Urrechaga,
More informationThe effect of losartan on hemoglobin concentration and renal outcome in diabetic nephropathy of type 2 diabetes
original article http://www.kidney-international.org & 2008 International Society of Nephrology The effect of losartan on hemoglobin concentration and renal outcome in diabetic nephropathy of type 2 diabetes
More informationROLE OF ANGIOTENSIN CONVERTING ENZYME INHIBITORS AND ANGIOTENSIN RECEPTOR BLOCKERS IN TYPE I DIABETIC NEPHROPATHY DR.NASIM MUSA
ROLE OF ANGIOTENSIN CONVERTING ENZYME INHIBITORS AND ANGIOTENSIN RECEPTOR BLOCKERS IN TYPE I DIABETIC NEPHROPATHY DR.NASIM MUSA Type I IDDM is characterized by The abrupt onset of symptoms Insulinopenia
More informationAnemia in the elderly. Nattiya Teawtrakul MD., PhD
Anemia in the elderly Nattiya Teawtrakul MD., PhD Contents Definition of anemia in the elderly The impact of anemia in the elderly Etiology of anemia in the elderly Management of anemia in the elderly
More informationTHE PROGNOSIS OF PATIENTS WITH CHRONIC KIDNEY DISEASE AND DIABETES MELLITUS
214 ILEX PUBLISHING HOUSE, Bucharest, Roumania http://www.jrdiabet.ro Rom J Diabetes Nutr Metab Dis. 21(3):23-212 doi: 1.2478/rjdnmd-214-25 THE PROGNOSIS OF PATIENTS WITH CHRONIC KIDNEY DISEASE AND DIABETES
More informationEffect of Anemia and Hyperhomocysteinemia on Mortality of Patients on Hemodialysis
Dialysis Effect of Anemia and Hyperhomocysteinemia on Mortality of Patients on Hemodialysis Muhammad Anees, 1 Asim Mumtaz, 2 Muhammad Ibrahim, 3 Seemab Mumtaz Shaheen, 4 Aneela Asghar 5 Original Paper
More informationThe incidence and prevalence of hypertension
Hypertension and CKD: Kidney Early Evaluation Program (KEEP) and National Health and Nutrition Examination Survey (NHANES), 1999-2004 Madhav V. Rao, MD, 1 Yang Qiu, MS, 2 Changchun Wang, MS, 2 and George
More informationACE Inhibitors and Protection Against Kidney Disease Progression in Patients With Type 2 Diabetes: What s the Evidence?
Reviews ACE Inhibitors and Protection Against Kidney Disease Progression in Patients With Type 2 Diabetes: What s the Evidence? George L. Bakris, MD; 1 and Matthew Weir, MD 2 Although angiotensin-converting
More informationIntravenous Iron Requirement in Adult Hemodialysis Patients
Intravenous Iron Requirement in Adult Hemodialysis Patients Timothy V. Nguyen, PharmD The author is a clinical pharmacy specialist with Holy Name Hospital in Teaneck, New Jersey. He is also an adjunct
More informationProfessor Suetonia Palmer
Professor Suetonia Palmer Department of Medicine Nephrologist Christchurch Hospital Christchurch 14:00-14:55 WS #108: The Kidney Test - When To Test and When to Refer ( and When Not To) 15:05-16:00 WS
More informationSLOWING PROGRESSION OF KIDNEY DISEASE. Mark Rosenberg MD University of Minnesota
SLOWING PROGRESSION OF KIDNEY DISEASE Mark Rosenberg MD University of Minnesota OUTLINE 1. Epidemiology of progression 2. Therapy to slow progression a. Blood Pressure control b. Renin-angiotensin-aldosterone
More informationK atching Up with KDOQI: Clinical Practice Guidelines & Clinical Practice Recommendations for Anemia of Chronic Kidney Disease 2006
K atching Up with KDOQI: Clinical Practice Guidelines & Clinical Practice Recommendations for Anemia of Chronic Kidney Disease 2006 Why new guidelines? Rationale for KDOQI Anemia 2006 Expand scope to all
More informationTime trends in the epidemiology of renal transplant patients with type 1 diabetes mellitus over the last four decades
Nephrol Dial Transplant (2006) 21: 770 775 doi:10.1093/ndt/gfi278 Advance Access publication 9 January 2006 Original Article Time trends in the epidemiology of renal transplant patients with type 1 diabetes
More informationOutpatient Management of Chronic Kidney Disease for the Internist
Outpatient Management of Chronic Kidney Disease for the Internist Annual Meeting of Maryland Chapter of the American College of Physicians February 3, 2018 MARY (TESSIE) BEHRENS, MD, FACP, FASN, FNKF MID-ATLANTIC
More informationEfficacy of Folic Acid in Anemia Treatment Among Hemodialysis Patients in Jakarta, Indonesia
Research Article Efficacy of Folic Acid in Anemia Treatment Among Hemodialysis Patients in Jakarta, Indonesia Diana Laila Ramatillah* 1, Syed Azhar Syed Sulaiman 1, Amer Hayat Khan 1, Ong Loke Meng 2,
More information